Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Patrick I Eacho"'
Autor:
Krista M. Schroeder, Thomas P. Beyer, Ryan J. Hansen, Bomie Han, Richard T. Pickard, Victor J. Wroblewski, Mark C. Kowala, Patrick I. Eacho
Publikováno v:
Journal of Lipid Research, Vol 56, Iss 11, Pp 2124-2132 (2015)
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact
Externí odkaz:
https://doaj.org/article/f9915123339b461b9a86c49a1bb6065e
Autor:
Bomie Han, Patrick I. Eacho, Michael D. Knierman, Jason S. Troutt, Robert J. Konrad, Xiaohong Yu, Krista M. Schroeder
Publikováno v:
Journal of Lipid Research, Vol 55, Iss 7, Pp 1505-1514 (2014)
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a secreted protein which regulates serum LDL cholesterol. It circulates in human and rodent serum in an intact form and a major truncated form. Previous in vitro studies involving the expressio
Externí odkaz:
https://doaj.org/article/c418d74c90224ffda7dbe266040357e4
Autor:
Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, Guoqing Cao
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 7, Pp 1488-1498 (2007)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined. We show here that recombinant human PCSK9 express
Externí odkaz:
https://doaj.org/article/e83e1b4f8a864a4c80a2187d406a793c
Autor:
Robert J. Schmidt, James V. Ficorilli, Youyan Zhang, Kelli S. Bramlett, Thomas P. Beyer, Kristen Borchert, Michele S. Dowless, Keith A. Houck, Thomas P. Burris, Patrick I. Eacho, Guosheng Liang, Li-wei Guo, William K. Wilson, Laura F. Michael, Guoqing Cao
Publikováno v:
Journal of Lipid Research, Vol 47, Iss 5, Pp 1037-1044 (2006)
Hypercholesterolemia is a major risk factor for coronary artery disease. Oxysterols are known to inhibit cholesterol biosynthesis and have been explored as potential antihypercholesterolemic agents. The ability of 3β-hydroxy-5α-cholest-8(14)-en-15-
Externí odkaz:
https://doaj.org/article/dde7296348914bc195be72f807c06492
Autor:
Daniel R. Jones, Robert J. Schmidt, Richard T. Pickard, Patricia S. Foxworthy, Patrick I. Eacho
Publikováno v:
Journal of Lipid Research, Vol 43, Iss 3, Pp 383-391 (2002)
Estrogen replacement therapy in women decreases hepatic lipase (HL) activity, which may account for the associated increase in HDL cholesterol. To investigate whether estrogen decreases HL transcription, transient cotransfection assays with HL promot
Externí odkaz:
https://doaj.org/article/8ca3c86fe334480e80531804c268c4c2
Publikováno v:
Journal of Lipid Research, Vol 41, Iss 9, Pp 1390-1401 (2000)
Our studies were conducted to explore the role of hepatic fatty acid-binding protein (L-FABP) in fatty acid transport to the nucleus. Purified rat L-FABP facilitated the specific interaction of [3H]oleic acid with the nuclei. L-FABP complexed with un
Externí odkaz:
https://doaj.org/article/dfefc0b5949849a2902b9e1647b120e1
Autor:
Michael J. Berna, Patrick I. Eacho, Ryan John Hansen, Thomas P. Beyer, Andrea E Sperry, Victor J. Wroblewski, Krista Schroeder
Publikováno v:
mAbs
A recent report described a novel mechanism of action for an anti-proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody (LY3015014, or LY), wherein the antibody has improved potency and duration of action due to the PCSK9 epitope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f329fd3fa05d9bccc02e341e2f483242
https://doi.org/10.1080/19420862.2016.1270490
https://doi.org/10.1080/19420862.2016.1270490
Autor:
Daniel J. Rader, Leonardo Cacciagiú, Laura Schreier, Ana Inés González, Verónica Miksztowicz, Mary G. McCoy, Alicia Elbert, Jeffrey T. Billheimer, Patrick I. Eacho, Gabriela Berg
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 32:3033-3040
Objective— A novel phospholipase assay was used to measure for the first time the behavior of endothelial and hepatic phospholipase activities in postheparin human plasma of hemodialyzed patients and its relationship with atherogenic and antiathero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49566945056a0b11e23b62da880e08c
https://doi.org/10.1161/atvbaha.112.300110
https://doi.org/10.1161/atvbaha.112.300110
Autor:
Joaquim Trias, Patrick I Eacho, Robert M. Christie, Reidy Charles Arthur, Colin Hislop, Heather Fraser, Kenneth E. Gould, Heather L Rick, Michael L Chouinard
Publikováno v:
Journal of Cardiovascular Pharmacology. 53:60-65
The family of secretory phospholipase A2 (sPLA2) enzymes has been associated with inflammatory diseases and tissue injury including atherosclerosis. A-001 is a novel inhibitor of sPLA2 enzymes discovered by structure-based drug design, and A-002 is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121b9449ee7d90de5bf7f5eb1ce54ee7
https://doi.org/10.1097/fjc.0b013e318195bfbc
https://doi.org/10.1097/fjc.0b013e318195bfbc
Autor:
Thomas P Beyer, Patrick I Eacho, Krista M Schroeder, Ryan J Hansen, Victor J Wroblewski, Bomie Han, Richard T Pickard, Mark C Kowala
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 35
Introduction: Monoclonal antibodies (Mabs) that neutralize proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to lower LDL-C in human trials. It is known that PCSK9 is cleaved by furin at Arg218 and that the cleaved PCSK9 is inacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2424fb404b29a0fb4d02ffe4974e6794
https://doi.org/10.1161/atvb.35.suppl_1.538
https://doi.org/10.1161/atvb.35.suppl_1.538